Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Sept 2026

Wang Kai, Yi Chao, Ning Xiong, Xiong Dalin, Wang Song, Wu Xiaoying, Bao Hua, Jiang Yuan, Deng Hongyu, Tang Faqing

Abstract excerpt

BACKGROUND: BRAF fusions are rare but clinically relevant oncogenic events in non-small cell lung cancer (NSCLC), yet their molecular characteristics and optimal management remain unclear. METHODS: We retrospectively analyzed 97 patients with NSCLC harboring kinase domain-retaining BRAF fusions, stratified into de novo (N = 43) and acquired (N = 54) groups. Clinical and genomic features were compared across...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Drug Resistance, Neoplasm

Share to Lung Neoplasms

Share to Oncogene Proteins, Fusion

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 42546514
DOI: 10.1016/j.lungcan.2026.109556

Genes

BRAF
EGFR
AGK
TRIM24
ALK
CTNNB1
DTNB
KMT2C
MKRN1
RET
TP53
ZC3HAV1
ZNF703

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer.PMID 42546514Read ↗

BRAF in Lung Cancers: Analysis of Patient Cases Reveals Recurrent BRAF Mutations, Fusions, Kinase Duplications, and Concurrent AlterationsSemantic proximity Read ↗

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.Semantic proximity Read ↗

RET Fusion-Positive Lung Adenocarcinoma: Partner-Specific Clinicopathological Characteristics, Co-Mutation Profiles, and Implications for Targeted and Immunotherapy.Semantic proximity Read ↗

Beyond ALK and ROS1: RET, NTRK, EGFR and BRAF gene rearrangements in non-small cell lung cancerSemantic proximity Read ↗

Oncogenic Fusions in NSCLC: From Mechanisms to Clinical ApplicationsSemantic proximity Read ↗

Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profilingSemantic proximity Read ↗

Diverse BRAF Gene Fusions Confer Resistance to EGFR-Targeted Therapy via Differential Modulation of BRAF ActivitySemantic proximity Read ↗

Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusionSemantic proximity Read ↗

Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications.Semantic proximity Read ↗

Common Oncogene Mutations and Novel SND1-BRAF Transcript Fusion in Lung Adenocarcinoma from Never Smokers.Semantic proximity Read ↗

Characterizing the molecular and clinical implications of NRG1 fusions in NSCLC through integrated RNA and DNA sequencing analysis.Semantic proximity Read ↗

Genomic characterization and outcome evaluation of kinome fusions in lung cancer revealed novel druggable fusionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.